350 rub
Journal Biomedical Radioelectronics №2 for 2014 г.
Article in number:
Terahertz therapy in cardiology. A 10-year experience of use
Keywords: angina pectoris electromagnetic radiation terahertz range nitrogen oxide
Authors:
S.S. Parshina - Dr.Sc.(Med.), Professor, Saratov State Medical University n.a. V.I. Razumovsky. E-mail: parshinasvetlana@rambler.ru
Abstract:
The results of 10-year studies of the THz electromagnetic radiation therapy of (150,176...150,664 GHz) nitrogen oxide molecular spectrum (THz-therapy-NO) efficiencyinpatients with angina, which gave occasion to serialize medical technique in 2009 (THz-therapy apparatus "Орбита", eng. orbite). The antianginal effect of THF-NO-therapy is extremely stable in cardiac patients and does not depend on the form of angina (stable, unstable), sex, age and the type of intermittent exposure. The two types of THF-NO-therapy exposure on hemostasis system and blood rheological properties: active antithrombotic and protection (preventing a developing of hypercoagulative chnges on the background of a standard drug therapy). Effect on a hemostasis system depends on a mode and duration of an exposition, severity of the initial state, age. The most sensitive to THz exposure is procoagulative component of hemostasis system. A decrease of course exposure leads to an expansion of antithrombotic influence due to an increase of activity of natural anticoagulants (antitrombin-III). The exposure mode of «3/15» is optimal, enabling to achieve the heart-rate-decelerative and antihypertensive effects. Concomitant hypertension requires shortening the decrease of the duration of the session to 21 minutes. Smoking does not affect the sensitivity to EMR THF.
Pages: 3-18
References

  1. Parshina S.S., Kirichuk V.F., Golovacheva T.V. i dr. Pervy'j opy't klinicheskogo primeneniya e'lektromagnitnogo izlucheniya teragerczevogo diapazona na chastotax molekulyarnogo spektra oksida azota // Biomediczinskie texnologii i radioe'lektronika. 2004. № 11. S. 46-54.
  2. Krenitskiy A. P. The problems of measuring the dielectric characteristics of nano- and micro- sized mediums in the terahertz frequency range 100-3000 GHz // in Successes of modern electronics. 2008. № 9. P. 30-35.
  3. Parshina S.S. Klinicheskie osobennosti ispol'zovaniya TGCh-terapii-NO u bol'ny'x stenokardiej // Biomediczinskie texnologii i e'lektronika. 2006. № 1. S. 4-11.
  4. Parshina S.S. Adaptaczionny'e mexanizmy' sistemy' gemostaza i reologii krovi u bol'ny'x razlichny'mi formami stenokardii: Avtoref. diss?.dokt. med. nauk // Saratov: SGMU. 2006. 48 s.
  5. Patent № 2286185 (RF). Sposob lecheniya serdechno-sosudisty'x zabolevanij / S.S. Parshina, V.F. Kirichuk, V.D. Tupikin i dr.
  6. Parshina S.S., Golovacheva T.V., Kirichuk V.F. i dr. E'ffektivnost' ispol'zovaniya e'lektromagnitnogo izlucheniya teragerczevogo diapazona na chastotax molekulyarnogo spektra oksida azota u bol'ny'x stabil'noj i nestabil'noj stenokardiej // Millimetrovy'e volny' v biologii i mediczine. 2008. № 1. S. 5-26.
  7. Vanin A.F. Oksid azota v biologii: istoriya, sostoyanie i perspektivy' issledovanij // Bioximiya. 1998. T. 63. Vy'p. 7. S. 867-869.
  8. Men'shhikova E.B., Zenkov N.K., Reutov V.P. Oksid azota i NO-sintazy' v organizme mlekopitayushhix pri razlichny'x fiziologichesix sostoyaniyax // Bioximiya. 2000. T. 65. Vy'p.4. S. 485-503.
  9. Vinogradov N.A. Antimikrobny'e svojstva okisi azota i regulyacziya ee biosinteza v makroorganizme // Antibiotiki i ximioterapiya. 1998. №43. V. 2. C.24-29.
  10. Nevzorova V.A., Zuga M.V., Gel'czer B.I. Rol' okisi azota v regulyaczii legochny'x funkczij // Terapevticheskij arxiv. 1997. № 3. S. 68-73.
  11. Kirichuk V.F., Kreniczkij A.P., Majborodin A.V. i dr. Oksid azota i e'lektromagnitnoe izluchenie KVCh // Biomediczinskie texnologii i radioe'lektronika. 2002. №10. S. 95-108.
  12. Kreniczkij A.P., Majborodin A.V., Beczkij O.V. i dr. Kvaziopticheskij KVCh-generator molekulyarny'x spektrov izlucheniya atmosferny'x gazov dlya issledovaniya fizicheskix i biologicheskix sred // Biomediczinskie texnologii i radioe'lektronika. 2002. № 12. S. 17-26.
  13. Vodolagin A.V. Patogeneticheskie osobennosti techeniya i korrekczii disseminirovannogo vnutrisosudistogo sverty'vaniya krovi u bol'ny'x stabil'noj stenokardiej vy'sokix funkczional'ny'x klassov: Avtoref. diss?.kand. med. nauk. Saratov. 2008. 25 s.
  14. Parshina S.S., Kirichuk V.F., Golovacheva T.V. Afanas'eva T.N i dr. Osobennosti vliyaniya TGCh-terapii-NO na funkczional'noe sostoyanie sistemy' gemostaza u bol'ny'x stenokardiej // Biomediczinskie texnologii i radioe'lektronika. 2006. № 3. S. 3-7.
  15. Parshina S.S.,  Golovacheva T.V., Afanas'eva T.N., Gluxova N.A. i dr. Osobennosti gemodinamicheskix e'ffektov teragerczevoj terapii u bol'ny'x stenokardiej razlichnogo pola // Biomediczinskaya radioe'lektronika. 2011. №8. S. 58-63.
  16. Parshina S.S., Vodolagin A.V., Kirichuk V.F., Afanas'eva T.N., Afanas'eva T.N., Golovacheva T.V., Tixonova S.A., Strel'nikova O.A., Vodolagina E.S. Osobennosti vozrastnoj chuvstvitel'nosti k volnam teragerczevogo diapazona u bol'ny'x stenokardiej // Millimetrovy'e volny' v biologii i mediczine. 2012. №1. S. 84-88.
  17. Parshina S.S., Afanas'eva T.N., Vodolagin A.V. i dr. Nekotory'e klinicheskie aspekty' vozdejstviya teragerczevoj terapii u bol'ny'x s tyazhely'mi formami stenokardii // Millimetrovy'e volny' v biologii i mediczine. 2012. №1. S. 65-73.
  18. Parshina S.S., Afanas'eva T.N., Tupikin V.D. i dr. Oksid azota i teragerczevoe izluchenie: perspektivy' klinicheskogo ispol'zovaniya // Novy'e informaczionny'e texnologii v mediczine, biologii, farmakologii i e'kologii. Trudy' XXI mezhdunar. konf. i diskussionnogo nauchnogo kluba. Ukraina. Jalta-Gurzuf. 2013. S. 112-115.
  19. Vodolagin A.V., Parshina S.S., Golovacheva T.V., Kirichuk V.F., Vodolagina E.S. Vliyanie TGCh-terapii-NO na sistemu gemostaza u bol'ny'x stabil'noj stenokardiej vy'sokix funkczional'ny'x klassov // Sb. dokladov 15-go Ross. simpoziuma s mezhdunar. uchastiem «Millimetrovy'e volny' v mediczine i biologii». M. 2009. S. 43-46.
  20. Dudek R., Wildhirt S., Confort A. et al. Inducible nitric oxide synthase activity in myocardium after myocardial infarction in rabbit // Biochem. byophys. Res. Commun. 1994. V. 205. P. 1671-1680.
  21. Matsumori A., Yamada T., Suzuki H. et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy // Brit. Heart J. 1994. V. 72. P. 561-566.
  22. Finbel S.M., Oddis C.V., Jacob T.D. et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide // Science. 1992. V. 257. P. 387-389.
  23. Balligand J.I., Kelly R.A., Marsden P.A. et. al. Control of cardiac muscle function by endogenous nitric oxide signalling system // Proc. Nat. Acad. Sci USA. 1993. V. 90. P. 347-351.
  24. Stokle Zh.-K., Myulle B., Andrianczitoxajna R. I. dr. Giperprodukcziya oksida azota v patofiziologii krovenosny'x sosudov // Bioximiya. 1998. V. 63(7). P. 976-983.
  25. Moncada S., Palmer R.U., Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology // Pharmacol rev. 1991. V. 43. P. 109-142.
  26. Fedorov V.I. Nekotory'e zakonomernosti biologicheskix e'ffektov submillimetrovogo izlucheniya // Sb. dokladov 15-go Ross. simpoziuma s mezhdunar. uchastiem «Millimetrovy'e volny' v mediczine i biologii». M.: IRE' RAN. 2009. S. 167-170.
  27. Bryune B., Sandau K., fon Kneten A. Apoptoticheskaya gibel' kletok i oksid azota: mexanizmy' aktivaczii i antagonisticheskie signal'ny'e puti // Bioximiya. 1998. T. 63. Vy'p. 7. S. 966-975.
  28. Maly'shev I.Ju., Manoxina E.B. Stress, adaptacziya i oksid azota // Bioximiya. 1998. T. 63. № 7. S. 992-1006.
  29. Shitikova A.S. Tromboczitarny'j gemostaz. SPb: Izd-vo SPbGMU. 2000. 227 s.
  30. Lyashhenko A.K. Sostoyanie bolezni i pervichny'j mexanizm lechebnogo vozdejstviya millimetrovy'x voln // Sb. dokladov 15-go Ross. simpoziuma s mezhdunar. uchastiem «Millimetrovy'e volny' v mediczine i biologii». M.: IRE' RAN. 2009. S. 163-166.